Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 6Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Melanoma 1Lymphoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Rituximab 66Cyclophosphamide 52fludarabine phosphate 26fludarabine 22Filgrastim 21Vincristine 19Methotrexate 19Melphalan 19Doxorubicin 18Radiotherapy 17Etoposide 17Prednisone 16Tacrolimus 15Whole-Body Irradiation 14Mycophenolic Acid 14Cytarabine 14Peripheral Blood Stem Cell Transplantation 13Gemcitabine 13Cyclosporine 13Antilymphocyte Serum 13Lenalidomide 12Busulfan 11Bortezomib 11Granulocyte Colony-Stimulating Factor 9Alemtuzumab 9sargramostim 8Dexamethasone 8Cord Blood Stem Cell Transplantation 8pembrolizumab 7ibritumomab tiuxetan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma × 1-dodecylpyridoxal × Clear all
NCT00785798 2022-04-04

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

Yale University

Phase 1/2 Terminated
17 enrolled 4 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡